The new vaccine is indicated for individuals who have been previously vaccinated with any COVID-19 vaccine and are 65 years or older, or 12 to 64 years of age with at least 1 underlying condition that ...

Moderna (NASDAQ: MRNA) stock represented the ticket to an investing win. The company brought its coronavirus vaccine from ...

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Tuesday that Moderna has agreed to a true ...

The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...

Moderna's (MRNA) new COVID vaccine approval targets a broader high-risk population. Check out why I see potential for a 25-40 ...

Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved ...

The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...

Several mRNA vaccine trials found a debilitating side effect, and now the Trump administration is cutting funding for more ...

The Food and Drug Administration has approved Moderna's new COVID-19 vaccine, days after the federal government tightened ...

NEXSPIKE becomes Moderna’s third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc.

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

Robert F. Kennedy Jr. continues his anti-vax crusade by cancelling million-dollar bird flu vaccine deal with Moderna.